Adsunib 12.5mg Capsule (Sunitinib)

Adsunib 12.5mg Capsule is an anticancer medicine prescribed to certain types of kidney cancer, gastrointestinal stromal tumor, pancreatic neuroendocrine tumors, and medullary thyroid cancer. It contains Sunitinib as an active ingredient that works by blocking the action of specific enzyme.

It effectively controls the progression of cancer, especially in the advance stages of cancer. It may take few weeks to few months to see the results so don't stop taking medicine on your own without informing your doctor.

Kidney Cancer,  Gastrointestinal stromal tumors

Like other anticancer medicines, Adsunib 12.5mg Capsule(Sunitinib 12.5mg) also has some common to severe side effects. These undesired symptoms observed in the body after taking this medicine and usually disappear with time as the body adjusts to the medicine.
Common Side Effects Include:
● Decreased appetite
● Mucositis
● High blood pressure
● Hand-foot syndrome
● Bleeding disorder
● Taste change
● Nausea
● Vomiting
● Weakness
● Fatigue
● Diarrhea
Above mentioned effects don't need any special medical attention, but if you observe them continually, talk to your doctor immediately.

The recommended dose Adsunib 12.5mg Capsule(Sunitinib 12.5mg) may vary according to the type & stage of cancer, or age, weight, and other health factors of the patients. This capsule should be swallowed as a whole with water and do not crush, chew, or open it. It is usually taken once a day, with or without food, at a fixed time each day. Don't miss a dose or double the dose to compensate for the missed dose.

Instructions if you miss a dose

● Motzer, R. J., Michaelson, M. D., Rosenberg, J., Bukowski, R. M., Curti, B. D., George, D. J., ... & Wilding, G. (2007). Sunitinib efficacy against advanced renal cell carcinoma. The Journal of urology, 178(5), 1883-1887.
● Motzer, R. J., Escudier, B., Gannon, A., & Figlin, R. A. (2017). Sunitinib: ten years of successful clinical use and study in advanced renal cell carcinoma. The oncologist, 22(1), 41-52.
● Raymond, E., Dahan, L., Raoul, J. L., Bang, Y. J., Borbath, I., Lombard-Bohas, C., ... & Ruszniewski, P. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine, 364(6), 501-513.
● Gan, H. K., Seruga, B., & Knox, J. J. (2009). Sunitinib in solid tumors. Expert opinion on investigational drugs, 18(6), 821-834.
● Rini, B. I. (2007). Sunitinib. Expert opinion on pharmacotherapy, 8(14), 2359-2369.